norbuprenorphine
norbuprenorphine结构式
|
常用名 | norbuprenorphine | 英文名 | norbuprenorphine |
|---|---|---|---|---|
| CAS号 | 78715-23-8 | 分子量 | 413.55000 | |
| 密度 | 1.27g/cm3 | 沸点 | 562.7ºC at 760 mmHg | |
| 分子式 | C25H35NO4 | 熔点 | 221-224ºC | |
| MSDS | N/A | 闪点 | 294.1ºC | |
| 符号 |
GHS02, GHS06, GHS08 |
信号词 | Danger |
| 英文名 | norbuprenorphine |
|---|---|
| 英文别名 | 更多 |
| 密度 | 1.27g/cm3 |
|---|---|
| 沸点 | 562.7ºC at 760 mmHg |
| 熔点 | 221-224ºC |
| 分子式 | C25H35NO4 |
| 分子量 | 413.55000 |
| 闪点 | 294.1ºC |
| 精确质量 | 413.25700 |
| PSA | 70.95000 |
| LogP | 3.62020 |
| 折射率 | 1.627 |
| 符号 |
GHS02, GHS06, GHS08 |
|---|---|
| 信号词 | Danger |
| 危害声明 | H225-H301 + H311 + H331-H370 |
| 警示性声明 | P210-P260-P280-P301 + P310-P311 |
| 危险品运输编码 | UN1230 - class 3 - PG 2 - Methanol, solution |
![[5α,7α]-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3,6-dimethoxy-α-methyl-6,14-ethenomorphinan-7-methanol结构式](https://image.chemsrc.com/caspic/354/22151-78-6.png)
![1-[(5α,7α)-3-methoxy-4,5-epoxy-18,19-dihydro-7-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-methoxy-6,14-ethenomorphinan-17-yl]ethanone结构式](https://image.chemsrc.com/caspic/325/1352741-85-5.png)
![[5α,7α]-17-acetyl-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-6-methoxy-α-methyl-6,14-ethenomorphinan-7-methanolamide结构式](https://image.chemsrc.com/caspic/287/1352741-86-6.png)
| norbuprenorphine上游产品 2 | |
|---|---|
| norbuprenorphine下游产品 1 | |
CAS号52485-79-7|
P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception.
J. Pharmacol. Exp. Ther. 343(1) , 53-61, (2012) Norbuprenorphine is a major metabolite of buprenorphine and potent agonist of μ, δ, and κ opioid receptors. Compared with buprenorphine, norbuprenorphine causes minimal antinociception but greater res... |
|
|
Chemical and enzyme-assisted syntheses of norbuprenorphine-3-β-D-glucuronide.
Bioconjug. Chem. 22(4) , 752-8, (2011) Norbuprenorphine-3-β-d-glucuronide (nBPN-3-β-d-G, 1) is a major phase II metabolite of buprenorphine, a pharmaceutical used for the treatment of opioid addiction. The pharmacological activity of compo... |
|
|
Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women.
Ther. Drug Monit. 33(5) , 619-26, (2011) Buprenorphine is currently under investigation as a pharmacotherapy to treat pregnant women for opioid dependence. This research evaluates buprenorphine (BUP), norbuprenophine (NBUP), buprenorphine-gl... |
| 6-Methylamino-4,4-diphenyl-3-heptanol-acetat |
| 7a-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydronororipavine |
| Noracetylmethadol |
| paracymethadol |
| Noracetylmethadone |
| Noracymethadole |
